Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma Clinical Trial

Official title:

A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03776812
• Other study ID #: CORT125134-552
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: January 28, 2019
• Est. completion date: March 2023

Study information

• Verified date: June 2022
• Source: Corcept Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.

Description:

Relacorilant is a small molecule antagonist of the glucocorticoid receptor (GR). The goals of this study are to evaluate the efficacy of relacorilant either administered daily (continuous) or on the day prior, the day of, and the day after chemotherapy (intermittent) in combination with nab-paclitaxel in the treatment of platinum-resistant ovarian, fallopian tube, or primary peritoneal cancers compared with nab-paclitaxel alone. The safety, pharmacokinetics (PK), and pharmacodynamic profile of relacorilant in combination with nab-paclitaxel will also be assessed.

Eligible patients will be randomized 1:1:1 to one of the following three treatment arms. Patient randomization will be stratified by treatment-free interval from most recent taxane (relapsed within 6 months vs >6 months) and presence of ascites (yes vs no).

• Arm A (Continuous relacorilant): Relacorilant starting at 100mg, administered orally, once daily every day in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.

• Arm B (Intermittent relacorilant): Relacorilant 150mg, administered orally, on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.

• Arm C (Comparator): Nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.

Patients will remain on study treatment until reaching a protocol-defined event of disease progression (PD), experiencing unmanageable toxicity, or until other treatment discontinuation criteria are met. All patients will be followed for progression, subsequent therapies and survival. Patients in Arm C who experience unequivocal PD per RECIST v1.1 will be given the opportunity to receive relacorilant in combination with nab-paclitaxel after discussion with the Medical Monitor.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 178
• Est. completion date: March 2023
• Est. primary completion date: March 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed and dated IRB/IEC-approved informed consent form (ICF) prior to study-specific screening procedures.

• Female patients aged = 18 years old at time of consent.

• Histologic diagnosis of high grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer or ovarian carcinosarcoma. Clear cell, mucinous and borderline histologic subtypes are excluded.

• Received at least one line of therapy with evidence of cancer progression within 6 months after the last dose of platinum-based therapy (i.e., having a platinum-free interval of <6 months [platinum resistant]), or progressive disease during or immediately after primary platinum-therapy, (i.e.platinum refractory). Patients with primary platinum resistance (progression within 6 months of the last dose of first-line platinum-containing chemotherapy) are considered eligible.

Notes: For the calculation of the platinum-free interval, cancer progression must be defined by clear evidence of progression, such as radiographic progression per RECIST v1.1. Calculating the platinum-free interval on the basis of increased CA-125 is not allowed.

• Measurable or non-measurable disease by RECIST v1.1:

• Previously irradiated lesions are not allowed as measurable disease, unless there is documented evidence of progression in the lesions.

• To be eligible with non-measurable disease, patients must have evaluable disease with CA 125 at least twice the upper limit of reference range (of CA-125 = 70 U/mL), along with radiographically evaluable disease by CT/MRI.

• Availability and consent to provide tumor tissue for biomarker assays (archival or recent biopsy).

• No more than 4 prior chemotherapeutic or myelosuppressive regimens (not including maintenance therapy such as single-agent bevacizumab or poly (ADP-ribose) polymerase [PARP] inhibitor). Patients with platinum-refractory cancer cannot have had more than 2 prior lines of treatment for refractory disease.

• Appropriate to treat with nab-paclitaxel, in the opinion of the Investigator.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

• Adequate organ and bone marrow function meeting the following criteria at the Screening Visit:

• Absolute neutrophil count (ANC) = 1,500 cells/mm3.

• Platelet count = 100,000/mm3.

• Hemoglobin = 9 g/dL.

• AST or ALT = 2.5 × upper limit of normal (ULN) (or = 5 × ULN in the context of liver metastasis).

• Total bilirubin = 1.5 × ULN.

• Creatinine clearance = 45 mL/min/1.73 m2 (measured or estimated).

• Albumin = 3 g/dL (= 30 g/L) .

• If patient has undergone surgery of the gastrointestinal or hepatobiliary tract, adequate absorption as evidenced by: albumin = 3.0 g/dL, controlled pancreatic insufficiency (if present), and lack of malabsorption.

• Able to swallow and retain oral medication and does not have uncontrolled emesis.

• Able to comply with protocol requirements.

• Negative pregnancy test for patients of childbearing potential. Patients of childbearing potential must use appropriate precautions to avoid pregnancy, defined as of non-childbearing potential (ie, postmenopausal or permanently sterilized) or using highly effective contraception with low user-dependency, for at least 3 months after the last dose of relacorilant, or per the duration indicated in the product label for nab-paclitaxel, whichever is latest. A woman is postmenopausal if it is more than 12 months since her last menstruation, without an alternative medical cause. Accepted methods of permanent sterilization methods are hysterectomy, bilateral salpingectomy and/or bilateral oophorectomy. Accepted methods of highly effective contraception with low user-dependency are:

• An IUD, provided that the subject has tolerated its use for at least 3 months before the first dose of study medication and undertakes not to have it removed for 1 month after the last dose.

• Abstinence from heterosexual intercourse, when it is in line with the subject's preferred and usual lifestyle. Periodic abstinence and withdrawal are NOT acceptable.

• Vasectomized partner provided that the partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success.

• Oral hormonal contraceptives are NOT permitted.

Exclusion Criteria:

• Clinically relevant toxicity from prior systemic anticancer therapies or radiotherapy that in the opinion of the Investigator has not resolved to Grade 1 or less prior to randomization.

• Any major surgery within 4 weeks prior to randomization. If subject received major surgery including (curative or palliative surgery), they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

• Treatment with the following prior to randomization:

• Concurrent treatment with other anticancer therapy including other chemotherapy, immunotherapy, radiotherapy, chemoembolization, targeted therapy, an investigational agent or the non-approved use of a drug or device within 28 days before the first dose of study drug.

• Hormonal anticancer therapies within 7 days of the first dose of study drug.

• Systemic, inhaled, or prescription strength topical corticosteroids within 21 days of the first dose of study drug. Short courses (= 5 days) for non-cancer-related reasons are allowed if clinically required (such as prophylaxis for CT).

• Received radiation to more than 25% of marrow-bearing areas.

• Toxicities of prior therapies (except alopecia) that have not resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 = Grade 1.

• Requirement for treatment with chronic or frequently used oral corticosteroids for medical conditions or illnesses (e.g., rheumatoid arthritis, immunosuppression after organ transplantation).

• History of severe hypersensitivity or severe reaction to either study drug.

• Peripheral neuropathy from any cause > Grade 1.

• Pregnant or lactating patients or patients expecting to conceive children within the projected duration of the trial, starting with the screening visit through at least 3 months after the last dose of relacorilant, or per the duration indicated in the product label for nab-paclitaxel, whichever is latest.

• Human immunodeficiency virus or current chronic/active infection with hepatitis C virus or hepatitis B virus, including:

• Patients with chronic or active hepatitis B as diagnosed by serologic tests are excluded from the study. In equivocal cases, hepatitis B or C polymerase chain reaction may be performed and must be negative for enrollment.

• Patient has a clinically significant uncontrolled condition(s) or which in the opinion of the Investigator may confound the results of the trial or interfere with the patient's participation, including but not limited to:

• Unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 6 months before study entry.

• Uncontrolled hypertension (sustained systolic blood pressure > 150 mmHg or diastolic pressure > 100 mmHg despite optimal management). Patients will be considered eligible if hypertension is treated and controlled during Screening.

• Active infection that requires parenteral antibiotics.

• Bowel obstruction or gastric outlet obstruction.

• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

• Untreated parenchymal central nervous system metastases.

• Any other concurrent cancer or a history of another invasive malignancy within the last 3 years that has a likelihood of recurrence of > 30% within the next 5 years. Adequately treated non-melanoma skin cancers or non-muscle invasive urothelial cancer or other tumors curatively treated with no evidence of disease are permissible.

• Are taking a concomitant medication that is a strong CYP3A inhibitor or inducer, or that is a substrate of CYP3A with a narrow therapeutic window.

• Concurrent treatment with mifepristone or other glucocorticoid receptor (GR) antagonists.

• Drugs with a narrow therapeutic ratio that are highly dependent on CYP3A for clearance should be avoided. Caution should be exercised when co-administering known inhibitors of CYP3A with relacorilant. Medicines/food known to strongly inhibit CYP3A should be avoided.

• Concurrent treatment on other investigational treatment studies for the treatment of ovarian, fallopian tube, or primary peritoneal cancer.

• Has received a live vaccine within 30 days of planned start of study therapy. Note:

Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

Related Conditions & MeSH terms

• Carcinoma
• Ovarian Neoplasms
• Recurrence
• Recurrent Fallopian Tube Carcinoma
• Recurrent Ovarian Cancer
• Recurrent Primary Peritoneal Carcinoma

Intervention

Drug:
• Relacorilant, 100mg QD
Relacorilant is supplied as capsules for oral dosing
• Nab-paclitaxel, 80mg/m^2
Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
• Nab-paclitaxel, 100mg/m^2
Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
• Relacorilant, 150mg QD
Relacorilant is supplied as capsules for oral dosing

Locations

Country	Name	City	State
Belgium	Site Reference ID/Investigator #109	Brussel
Belgium	Site Reference ID/Investigator #119	Edegem
Belgium	Site Reference ID/Investigator #108	Leuven
Canada	Site Reference ID/Investigator #096	Montréal	Quebec
Canada	Site Reference ID/Investigator #117	Toronto	Ontario
Italy	Site Reference ID/Investigator #122	Milan
Italy	Site Reference ID/Investigator #112	Napoli
Italy	Site Reference ID/Investigator #124	Roma
Spain	Site Reference ID/Investigator #115	Barcelona
Spain	Site Reference ID/Investigator #114	Madrid
Spain	Site Reference ID/Investigator #116	Madrid
Spain	Site Reference ID/Investigator #113	Valencia
United States	Site Reference ID/Investigator #004	Birmingham	Alabama
United States	Site Reference ID/Investigator #106	Boston	Massachusetts
United States	Site Reference ID/Investigator #135	Charlottesville	Virginia
United States	Site Reference ID/Investigator #001	Chicago	Illinois
United States	Site Reference ID/Investigator #032	Denver	Colorado
United States	Site Reference ID/Investigator #121	Milwaukee	Wisconsin
United States	Site Reference ID/Investigator #051	New York	New York
United States	Site Reference ID/Investigator #127	Pittsburgh	Pennsylvania
United States	Site Reference ID/Investigator #038	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Corcept Therapeutics

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  Italy,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS)	Time from randomization until the date first documented of progressive disease (PD) by RECIST v1.1 (as determined by the Investigator at the local site), or death due to any cause, whichever occurs first	12 months from enrollment of last subject
Secondary	Objective Response Rate (ORR)	Proportion of patients with measurable disease at baseline who attain complete response (CR) or partial response (PR) by RECIST v1.1 (confirmation not required).	12 months from enrollment of last subject
Secondary	Duration of Response (DoR)	Time from when response (CR or PR) was first documented to first objectively documented PD or death (whichever occurs first)	12 months from enrollment of last subject
Secondary	Response according to Gynecological Cancer Intergroup criteria (GCIG)	Overall response per Gynecological Cancer Intergroup criteria (GCIG)	12 months from enrollment of last subject
Secondary	Best Overall Response (BoR)	Best response recorded from the date of randomization until PD/recurrence (or death)	12 months from enrollment of last subject
Secondary	Progression Free Survival (PFS) Rate	Proportion of patients who have not progressed at 6 and 12 months	12 months from enrollment of last subject
Secondary	PFS in patients who crossover to continuous treatment at time of PD	Time from randomization until the earliest date of progressive disease (PD) by RECIST v1.1, as determined by the Investigator at the local site, or death from any cause, whichever occurs first	12 months from enrollment of last subject
Secondary	Overall Response Rate in patients who crossover to continuous treatment at time of PD	Proportion of patients with measurable disease at baseline who attain confirmed complete response (CR) or partial response (PR) by RECIST v1.1	12 months from enrollment of last subject
Secondary	Duration of Response in patients who crossover to continuous treatment at time of PD	Time from when response (CR or PR) was first documented to first objectively documented PD or death (whichever occurs first)	12 months from enrollment of last subject
Secondary	Best Overall Response in patients who crossover to continuous treatment at time of PD	Proportion of patients with measurable disease at baseline who attain CR or PR by RECIST v1.1	12 months from enrollment of last subject
Secondary	Cancer Antigen (CA)-125 Response	CA-125 response will be assessed per GCIG criteria defined as >/=50% reduction in CA-125 from a pre-treatment sample and maintained for >/- 28 days in patients with a pre-treatment sample that is at least twice the upper limit of the reference range and within 2 weeks before starting the treatment. In addition, patients who have a CA-125 response and whose CA-125 level falls to within the reference range will be classified as CA-125 complete responders.	12 months from enrollment of last subject
Secondary	Overall survival	Time from randomization to death by any cause	12 months from enrollment of last subject
Secondary	Combined Response according to RECIST v1.1 + GCIG criteria	To assess combined response by RECIST 1.1 with GCIG criteria	12 months from enrollment of last subject